# A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea

> **NCT00649415** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 154 (actual)

## Conditions studied

- Dysmenorrhea

## Interventions

- **DRUG:** piroxicam
- **DRUG:** valdecoxib

## Key facts

- **NCT ID:** NCT00649415
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2018-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00649415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00649415, "A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00649415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*